TIDMMTPH

RNS Number : 9657E

Midatech Pharma PLC

12 July 2021

12 July 2021

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech Strengthens Management Team

with

Appointment of Dr Dmitry Zamoryakhin as Chief Scientific Officer

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.

Dr Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Officer of Oxford Biomedica plc (LON: OXB), having previously held positions of increasing responsibility at Grunenthal GmbH, Daiichi Sankyo Company Limited (TYO: 4568), Ono Pharmaceutical Co., Limited (TYO: 4528) and GlaxoSmithKline plc (LON:GSK, NYSE: GSK). He qualified as a doctor of medicine at Perm State Medical Academy, Russia, before earning a diploma in Pharmaceutical Medicine at PHARMED, Universite Libre de Bruxelles, and an MBA at Warwick Business School.

Dr Zamoryakhin will take over from Steve Damment, EVP R&D who, after six years with the Company, has decided to retire from full-time employment at the end of September 2021.

Commenting, Stephen Stamp, CEO and CFO of Midatech said : "I am delighted to welcome Dmitry to the Midatech team. He is a medic, was big pharma trained and has been biotech battle hardened. His breadth of experience will be invaluable as we move our Q-Sphera programmes and MTX110 through proof of concept to partnering.

"On behalf of everybody at Midatech, I should also like to express our thanks to Steve Damment for his service to the Company and, in particular, the key role he has played in championing MTX110."

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)29 2048 0180 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 Tel: +44 (0)20 7886 2500 
 
 Turner Pope Investments (TPI) Limited (Joint Broker) 
 Andrew Thacker / James Pope (Corporate Broking) 
  Tel: +44(0)20 3657 0050 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Maxwell Colbert 
  Tel: +1 (646) 653 7028 
  Email: mcolbert@edisongroup.com 
           About Midatech Pharma PLC 
            Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
            MTP) is a drug delivery technology company focused on improving 
            the bio-delivery and bio-distribution of medicines. The Company 
            combines approved and development medications with its proprietary 
            and innovative drug delivery technologies to provide compelling 
            products that have the potential to powerfully impact the 
            lives of patients. 
            The Company has developed three in-house technology platforms, 
            each with its own unique mechanism to improve delivery of 
            medications to sites of disease. All of the Company's technologies 
            have successfully entered human use in the clinic, providing 
            important validation of the potential for each platform: 
             *    Q-Sphera(TM) platform: a disruptive micro-technology 
                  used for sustained release to prolong and control the 
                  release of therapeutics over an extended period of 
                  time (from weeks to months). 
 
 
             *    MidaSolve(TM) platform: an innovative nanotechnology 
                  used to dissolve insoluble drugs so that they can be 
                  administered in liquid form directly and locally into 
                  tumours. 
 
 
             *    MidaCore(TM) platform: a leading-edge nanotechnology 
                  used for targeting medications to sites of disease. 
 
 
 
            The platform nature of the technologies offers the potential 
            to develop multiple drug assets rather than being reliant 
            on a limited number of programmes. Midatech's technologies 
            are supported by 36 patent families including 120 granted 
            patents and an additional 70 patent applications. Midatech's 
            headquarters and R&D facility is in Cardiff, UK. For more 
            information please visit www.midatechpharma.com 
            Forward-Looking Statements 
 
            Certain statements in this press release may constitute "forward-looking 
            statements" within the meaning of legislation in the United 
            Kingdom and/or United States Private Securities Litigation 
            Reform Act. All statements contained in this press release 
            that do not relate to matters of historical fact should be 
            considered forward-looking statements. 
 
            Reference should be made to those documents that Midatech 
            shall file from time to time or announcements that may be 
            made by Midatech in accordance with the London Stock Exchange 
            AIM Rules for Companies ("AIM Rules"), the Disclosure and 
            Transparency Rules ("DTRs") and the rules and regulations 
            promulgated by the US Securities and Exchange Commission, 
            which contains and identifies other important factors that 
            could cause actual results to differ materially from those 
            contained in any projections or forward-looking statements. 
            These forward-looking statements speak only as of the date 
            of this announcement. All subsequent written and oral forward-looking 
            statements by or concerning Midatech are expressly qualified 
            in their entirety by the cautionary statements above. Except 
            as may be required under the AIM Rules or the DTRs or by relevant 
            law in the United Kingdom or the United States, Midatech does 
            not undertake any obligation to publicly update or revise 
            any forward-looking statements because of new information, 
            future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPUPPMUPGGWP

(END) Dow Jones Newswires

July 12, 2021 09:30 ET (13:30 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Midatech Pharma Charts.
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Midatech Pharma Charts.